MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
(WorldNews Belgium)

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - March 21, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Lab21 Clinical Laboratory`s urology clients in the United Kingdom. Under the terms of the agreement, Lab21 will serve as a non-exclusive distributor for SelectMDx in the United Kingdom. Liquid biopsy samples will be tested in MDxHealth`s state-of-the-art clinical diagnostic laboratory in Nijmegen, The Netherlands. Lab21 will reimburse MDxHealth for all testing services performed. `In the UK, about 40,000 men a year undergo an...